Hossein Panjideh - Search Results

Year	Number of Results
2007	2
2008	2
2012	1
2014	1
2017	1
2022	2
2025	0

1

Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478.

Panjideh H, Niesler N, Weng A, Fuchs H. Panjideh H, et al. Toxins (Basel). 2022 Oct 13;14(10):703. doi: 10.3390/toxins14100703. Toxins (Basel). 2022. PMID: 36287991 Free PMC article.

2

Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies.

Fuchs H, Niesler N, Trautner A, Sama S, Jerz G, Panjideh H, Weng A. Fuchs H, et al. Among authors: panjideh h. Biomedicines. 2017 Mar 29;5(2):14. doi: 10.3390/biomedicines5020014. Biomedicines. 2017. PMID: 28536357 Free PMC article. Review.

3

Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.

Panjideh H, Niesler N, Weng A, Fuchs H. Panjideh H, et al. Toxins (Basel). 2022 Jul 13;14(7):478. doi: 10.3390/toxins14070478. Toxins (Basel). 2022. PMID: 35878216 Free PMC article.

4

Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.

Panjideh H, Müller G, Koch M, Wilde F, Scheu S, Moldenhauer G, Lipp M. Panjideh H, et al. Int J Cancer. 2014 Dec 1;135(11):2623-32. doi: 10.1002/ijc.28893. Epub 2014 Apr 29. Int J Cancer. 2014. PMID: 24729415

5

Production of bifunctional single-chain antibody-based fusion proteins in Pichia pastoris supernatants.

Panjideh H, Coelho V, Dernedde J, Fuchs H, Keilholz U, Thiel E, Deckert PM. Panjideh H, et al. Bioprocess Biosyst Eng. 2008 Oct;31(6):559-68. doi: 10.1007/s00449-008-0203-y. Epub 2008 Feb 6. Bioprocess Biosyst Eng. 2008. PMID: 18253756

6

Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.

Panjideh H, Da Silva Coelho VC, Dernedde J, Bachran C, Förster GJ, Franke J, Fasold P, Fuchs H, Thiel E, Deckert PM. Panjideh H, et al. Int J Oncol. 2008 Apr;32(4):925-30. Int J Oncol. 2008. PMID: 18360720

7

Targeted tumor therapy with a fusion protein of an antiangiogenic human recombinant scFv and yeast cytosine deaminase.

Schellmann N, Panjideh H, Fasold P, Bachran D, Bachran C, Deckert PM, Fuchs H. Schellmann N, et al. Among authors: panjideh h. J Immunother. 2012 Sep;35(7):570-8. doi: 10.1097/CJI.0b013e31826b1fb4. J Immunother. 2012. PMID: 22892453

8

Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.

Coelho V, Dernedde J, Petrausch U, Panjideh H, Fuchs H, Menzel C, Dübel S, Keilholz U, Thiel E, Deckert PM. Coelho V, et al. Among authors: panjideh h. Int J Oncol. 2007 Oct;31(4):951-7. Int J Oncol. 2007. PMID: 17786329

9

A33scFv-green fluorescent protein, a recombinant single-chain fusion protein for tumor targeting.

Petrausch U, Dernedde J, Coelho V, Panjideh H, Frey D, Fuchs H, Thiel E, Deckert PM. Petrausch U, et al. Among authors: panjideh h. Protein Eng Des Sel. 2007 Dec;20(12):583-90. doi: 10.1093/protein/gzm043. Epub 2007 Nov 22. Protein Eng Des Sel. 2007. PMID: 18033820

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year